English: Thank you for the comments and for the question. Of course, I monitor the use and the impact of the fund. It's important not just to have a statement where we can say we've made a promise and we've delivered on it. We then need to make sure it's doing what we thought it would do and providing that real benefit for individuals across the country. And, in doing that, there'll be money for each health board. I want to ensure that every health board gets a proper share of the resource, but then has a proper expectation that they'll deliver against that. This isn't just money to go into the pot to do what they want with. That's why it is going to be ring-fenced. That's why there will be directions. That's why we will be monitoring the use and the impact of the money. The AWMSG process has been successful for us in Wales. At least 29 new medicines have been available much quicker than NICE have been able to do for the whole of the UK as well. So, that's a real benefit in our ability to have medication available on an earlier basis in Wales. This will add to that as well. Part of the challenge has been on delivering patient access schemes - the point about the benefit and the cost between the public purse, the company and the individual who could benefit from the treatment. That does mean that I have difficult conversations sometimes with the pharmaceutical industry. I want to see that improve as we go through. The information that I've had about the issue you raised about Roche and Avastin has been about the challenge over the provision of information, the time that should be provided, the ability and the willingness to sign up to a patient access scheme, but then also about the conversations about how that information is transferred between the two. I'd be very happy to have a conversation with you to respond to information about what's happened in a particular case, but also for the future as well, because I do want to see that maturity in relation to what I've described being developed and continuing for the future. Because, as I say, it's in the interests of the industry; but equally, it's in the interests of the NHS and the patients that we're here to serve as well.
Welsh: Diolch am y sylwadau ac am y cwestiwn. Wrth gwrs, rwy'n monitro defnydd ac effaith y gronfa. Mae'n bwysig, nid yn unig i gael datganiad lle y gallwn ddweud ein bod wedi gwneud addewid a'i gyflawni. Mae angen i ni wedyn sicrhau ei fod yn gwneud yr hyn yr oeddem yn meddwl y byddai'n ei wneud ac yn darparu'r budd gwirioneddol hwnnw i unigolion ledled y wlad. Ac, wrth wneud hynny, y bydd arian ar gyfer pob bwrdd iechyd. Rwy'n dymuno sicrhau bod pob bwrdd iechyd yn cael cyfran briodol o'r adnodd, ond wedyn bod disgwyliad priodol y byddan nhw'n cyflawni yn sgil hynny. Nid arian mo hwn i'w roi yn y pot a gwneud fel y mynnont ag ef. Dyna pam y bydd yn cael ei neilltuo. Dyna pam y bydd yna gyfarwyddiadau. Dyna pam y byddwn yn monitro defnydd ac effaith yr arian. Mae'r broses AWMSG wedi bod yn llwyddiannus i ni yng Nghymru. Mae o leiaf 29 o feddyginiaethau newydd wedi bod ar gael yn gyflymach o lawer nag y mae NICE wedi gallu ei wneud ar gyfer y DU gyfan hefyd. Felly, mae hynny'n fantais wirioneddol yn ein gallu ni i sicrhau bod meddyginiaethau ar gael yn gynharach yng Nghymru. Bydd hyn yn ychwanegu at hynny hefyd. Mae rhan o'r her wedi ymwneud â chyflawni cynlluniau mynediad i gleifion - y pwynt am y budd a'r gost rhwng y pwrs cyhoeddus, y cwmni a'r unigolyn a allai elwa ar y driniaeth. Mae hynny'n golygu fy mod yn cael trafodaethau anodd weithiau â'r diwydiant fferyllol. Rwy'n dymuno gweld hyn yn gwella wrth i ni fynd rhagddi. Mae'r wybodaeth yr wyf wedi'i chael am y mater a godwyd gennych ynglŷn â Roche ac Avastin wedi ymwneud â'r her o ddarparu gwybodaeth, yr amser y dylid ei neilltuo, y gallu a'r parodrwydd i ymuno â chynllun mynediad i gleifion, ond wedyn hefyd am y trafodaethau ynglŷn â sut y mae'r wybodaeth honno'n cael ei throsglwyddo rhwng y ddau. Byddwn yn hapus iawn i drafod â chi er mwyn ymateb i wybodaeth am yr hyn sydd wedi digwydd mewn achos penodol, ond hefyd ar gyfer y dyfodol, oherwydd mae arnaf eisiau gweld yr aeddfedrwydd hwnnw mewn cysylltiad â'r hyn yr wyf wedi'i ddisgrifio yn cael ei ddatblygu, ac yn parhau yn y dyfodol. Oherwydd, fel y dywedais, mae er budd y diwydiant; ond yn yr un modd, mae er budd y GIG a'r cleifion yr ydym ni yma i'w gwasanaethu hefyd.